Anti-viral fusion peptides

a technology of anti-viral fusion and peptides, applied in the field of protein molecules, can solve problems such as complete waste of exercise, and achieve the effects of reducing symptoms and infectivity, reducing free virus in circulation, and reducing free gp120 in circulation

Inactive Publication Date: 2011-04-07
PRENDERGAST KENNETH FRANCIS
View PDF0 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present disclosure provides novel hybrid or fusion peptides having a minimum of two different peptide components possessing different functionality. One component, preferably the CD4 molecule or segment or derivative thereof which, is capable of binding to an HIV virus is fused or joined to a malaria derived peptide or derivative or fragment thereof which is capable of binding to a red cell membrane. The fusion peptide will in one aspect bind the free HIV virus to a red cell producing possible therapeutics benefits of:a) reduced free virus in circulation;b) reduced free GP120 in circulation;c) reduced symptoms and infectivity, both generally and prior to delivery;d) augmented therapeutic usefulness of blood tranfusions;e) greater safety of blood tranfusions;f) immune augmentation by novel vaccine effects;g) usefulness as prophylaxis, eye drops for theatre staff; preparations, creams, lotions and foams for contraceptive use; preparations for exposed cuts or abrasions;h) simpler safer and economic viral titre measurements;i) preparation for cleaning surgical instruments.

Problems solved by technology

It will be appreciated that although this step is not essential to the present disclosure, immobilisation being sufficient, nevertheless were a virus to attempt infection of a red cell such infection resulting in the dismantling of the virus outer coat and the incorporation of the virus RNA into the red cell cytoplasm this would be a completely wasted exercise from the viral point of view.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-viral fusion peptides
  • Anti-viral fusion peptides
  • Anti-viral fusion peptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Clinical Mode of Use

The molecular machines of the present disclosure in one aspect are prepared and packaged in lypholised form and stored in refridgerated conditions. The lypholised fusion peptides are reconstituted by means of injectable solvents such as injectable preparations of normal saline or dextrose 5% or the like together with buffers and other stabilising ingredients incorporated as necessary.

The reconstituted molecular machines (fusion peptides) are administered to patients by either the Direct or Indirect method.

Direct method involves the intravenous or even intra muscular administration of the reconstituted injectable solution of the molecular machines of amounts usually not exceeding 1,000 mg of agent per ml. The agents may be infused slowly by means of an intravenous drip or when safe to do so or if necessary by bolus injection.

The slower administration rates provide more even mixing of agent with red cells therefore labelling many more red cells.

A disadvantage wi...

example 2

The agents may be formulated in slow release forms allowing the gradual leaching of active peptide molecular machines over a time period. Examples of such methods are the incorporation of the agents into biodegradable polymers. Such polymers could be injected as subdermal ‘rice grains’ or form part of an intrauterine contraceptive device.

Intrauterine contraceptive devices (IUD'S) impregnated with the agents of the present disclosure would slowly leak the agents towards the cervix. Cerival erosions are known to be an area of major importance in women's vulnerability to AIDS. Indeed the heavier menses associated with IUD's would leach more of the peptides from the polymer and by targetting menstrual blood or on their own provide a useful degree of protection against the virus. Such a use would be very helpful in the Third World.

For a useful reference on polymer delivery systems see Kost J and Langer R Tibech April 1992 Vol 10, 127-131 incorportated fully herein by reference.

example 3

The novel peptide agents of the present disclosure may by incorporated into creams and gels or foams for use as topical preparations. Such compositions may be used in conjunction with:a) barrier contraceptives;b) in place of existing lubricating agents or with lubricating agents generally

The said creams, gels or foams may also be used to dress wounds, cuts or open sores or as contraceptive agents or in conjunction with contraceptives especially barrier methods. In the case of HIV positive patients such sores would become reduced sources of infection for others.

In the case of medical personnel such creams, gels or foams and the like could render abrasions or cuts more protected against contamination by free virus from patients. Such a mode of use as a prophylactic may be especially helpful for theatre personnel.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
psychological stressaaaaaaaaaa
binding affinityaaaaaaaaaa
Login to view more

Abstract

Hybrid peptides capable of binding a blood borne virus to a red cell, comprising a viral binding peptide component and a malaria merozoite red cell peptide binding component.

Description

FIELD OF INVENTIONThe field of this invention relates to protein molecules in particular hybrid protein molecules for the prevention of treatment of human beings afflicted with AIDS and diseases caused by Human Immuno Deficiency Viruses especially types 1 and 2; and other blood borne pathogens.BACKGROUND ARTThe AIDS syndrome is widely believed by the majority of Scientists (with a few exceptions) to be the end result of infection with Human Immuno Deficiency Virus type 1 or 2. Despite available treatment, on diagnosis of AIDS, life expectancy is short and death occurs usually within two years—death resulting from overwhelming infection and / or neoplastic diseases provoked by a profound immuno deficiency. The causative agent of this condition the HIV virus was proposed by Montagnier L and by Barre-Sinoussi F et al 1983, Science 220, 868-870 and slightly later by Gallo R et al 1983, Science 220 865-867.The accepted view of most Scientists is that this virus is necessary at least in par...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17A61P31/18
CPCC07K14/70514C07K2319/33C07K2319/32A61P31/18Y02A50/30
Inventor PRENDERGAST, KENNETH FRANCIS
Owner PRENDERGAST KENNETH FRANCIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap